We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Affymetrix, Inc. | NASDAQ:AFFX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 14.01 | 0 | 01:00:00 |
From May 2019 to May 2024
Affymetrix Inc. (AFFX) said it won clearance from the U.S. Food and Drug Administration for the addition of new gene expression reagents as accessories to its genetic analysis tools.
Shares were up 6.4% at $6.55 in recent premarket trading. The stock through Friday's close is up 22% this year.
The company, whose products are used by pharmaceutical, diagnostic and biotechnology companies, is aiming to generate at least a quarter of its 2011 revenue from new markets, including cytogenetics and cancer.
Affymetrix in April swung to a small first-quarter profit on lower expenses, though revenue declined more than Wall Street expected.
-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com
1 Year Affymetrix Chart |
1 Month Affymetrix Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
